bristol-myers squibb

Among leading biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG), Onyx Pharmaceuticals (NASDAQ: ONXX) and Vertex Pharmaceuticals (NASDAQ: VRTX) saw significant percentage declines in short interest between the July 31 and August 15 settlement dates. Short sellers also shied away...

Don’t expect to get a direct answer from any of the big pharma firms, but in the world of big data, the answer, or something pretty close to answer, was found by doing some simple math. Last year, Forbes columnist Matthew Herper went back to the basics and simply divided each company’s spending...

The earnings crunch continues this week. Reports are due from the likes of Apple (NASDAQ: AAPL), Caterpillar (NYSE: CAT) and General Motors (NYSE: GM), which are expected to say their earnings were lower than a year ago. On the other hand, Amazon.com (NASDAQ: AMZN), Facebook (NASDAQ: FB), Ford (...

Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest between the May 31 and June 14 settlement dates. The number of shares sold short in Onyx Pharmaceuticals (NASDAQ: ONXX), Pharmacyclics (NASDAQ: PCYC) and Regeneron...

Among biotech and emerging pharmaceutical companies, Biogen Idec (NASDAQ: BIIB), saw the most significant rise in short interest between the May 15 and May 31 settlement dates. The number of shares sold short in Amgen (NASDAQ: AMGN), Dendreon (NASDAQ: DNDN), Onyx Pharmaceuticals (NASDAQ: ONXX)...

It is not unusual for stocks on a tear to overrun their mean price targets, which is a signal of how far analysts on average expect the share price to climb. Some of the top-performing health care stocks over the past six months that pay dividends, such as Becton, Dickinson (NYSE: BDX), Bristol-...

Among biotech and emerging pharmaceutical companies, Regeneron Pharmaceuticals (NASDAQ: REGN) and Vertex Pharmaceuticals (NASDAQ: VRTX) saw he most significant rise in short interest between the April 30 and May 15 settlement dates. The number of shares sold short in Alexion Pharmaceuticals (...

The short interest moves in biotech and emerging pharmaceutical companies were mixed in the latter two weeks of April. The number of shares sold short in Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Illumina (NASDAQ: ILMN), Onyx Pharmaceuticals (NASDAQ: ONXX) and VIVUS (NASDAQ: VVUS)...

The short interest moves in biotech and emerging pharmaceutical companies were mixed in the first two weeks of April. The number of shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), Amgen (NASDAQ: AMGN), Biogen Idec (NASDAQ: BIIB), Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD...

The Supreme Court is skeptical and that is never a good thing. During arguments Monday, several justices suggested drugmakers may be open to lawsuits over payments made to generic manufacturers that the Federal Trade Commission says are designed to forestall generic versions of drugs. The...

The focus was on the big banks last week, with Goldman Sachs (NYSE: GS), J.P. Morgan (NYSE: JPM) and Morgan Stanley (NYSE: MS) reporting strong results, but Bank of America (NYSE: BAC) and Citigroup (NYSE: C) not so much. The spotlight is on tech earnings this week. Analysts anticipate lower per-...

The short interest in biotech and emerging pharmaceutical companies was mixed in the final two weeks of October. Shares sold short in Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Illumina (NASDAQ: ILMN) and VIVUS (NASDAQ: VVUS) grew somewhat between...

There are lots more on the earnings calendar this week, including results from Apple (NASDAQ: AAPL) for the three months that included the release of the iPhone 5. Monday Results from Caterpillar (NYSE: CAT) and Yahoo! (NASDAQ: YHOO) will be the highlights on Monday, and analysts expect to see...

The earnings crunch rolls on. Analysts are looking for strong earnings growth in this week's quarterly reports from Apple, Caterpillar, Starbucks and Visa. But ConocoPhillips, Ford and Netflix are among those expected to post significantly lower per-share earnings, compared to the same period of a...